趋化因子受体4与肿瘤(此篇文章已撤销)

doi:10.3760/cma.j.issn.1673-422X.2014.04.009

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (3): 190-193.doi: 10.3760/cma.j.issn.1673-422X.2014.04.009

趋化因子受体4与肿瘤(此篇文章已撤销)

马亚南, 王宝红, 许晓群, 王郡甫

250062 济南，山东省医学科学院基础医学研究所, 济南大学山东省医学科学院医学与生命科学学院（马亚南、许晓群、王郡甫）；山东省临沂市中医医院感染管理科（王宝红）

出版日期:2014-03-08 发布日期:2014-03-17
通讯作者: 王郡甫，E-mail：wjf_1030@126.com E-mail:wjf_1030@126.com
基金资助:
山东省自然科学基金（ZR2009CM036、ZR2010CM067）；山东省大型科学仪器设备升级改造技术研究专项（2013SJGZ09）

Chemokine receptor 4 and tumors

MA Ya-nan, WANG Bao-Hong, XU Xiao-Qun, WANG Jun-Fu

Institute of Basic Medicine, Shandong Academy of Medical Sciences; School of Medicine and Life Sciences, University of Ji′nanShandong Academy of Medical Sciences, Ji′nan 250062, China

Online:2014-03-08 Published:2014-03-17
Contact: Wang Junfu, E-mail: wjf_1030@126.com E-mail:wjf_1030@126.com

摘要/Abstract

摘要： 趋化因子受体4（CXCR4）属于G蛋白耦联受体超家族，具有趋化免疫细胞、维持免疫细胞的动态平衡等生物学作用。CXCR4表达于多种类型的组织和细胞，在多种肿瘤及肿瘤的不同阶段，CXCR4的表达都明显高于正常组织。CXCR4与肿瘤细胞的增殖、黏附、侵袭和转移有关，在肿瘤的进展中发挥重要作用。

关键词: 受体, CXCR4, 肿瘤转移, 趋化因子CXCL12

Abstract: Chemokine receptor 4 (CXCR4) belongs to G proteincoupled receptor superfamily. It can induce immune cells directed chemotaxis and keep their homeostasis. CXCR4 expresses on a variety of tissues and cells. In different tumors and at different stages of tumor, CXCR4 expression is significantly higher than that in normal tissue. CXCR4 plays an important role in tumor progression since it is involved in tumor cell proliferation, adhesion, invasion and metastasis.

Key words: Receptors, CXCR4, Neoplasm metastasis, Chemokine CXCL12

马亚南, 王宝红, 许晓群, 王郡甫. 趋化因子受体4与肿瘤(此篇文章已撤销)[J]. 国际肿瘤学杂志, 2014, 41(3): 190-193.

MA Ya-nan, WANG Bao-Hong, XU Xiao-Qun, WANG Jun-Fu. Chemokine receptor 4 and tumors[J]. Journal of International Oncology, 2014, 41(3): 190-193.

参考文献

［1］ Sauve K, Lepage J, Sanchez M, et al. Positive feedback activation of estrogen receptors by the CXCL12CXCR4 pathway［J］. Cancer Res, 2009, 69(14): 57935800. ［2］ Romagnani P, Lasagni L, Annunziato F, et al. CXC chemokines: the regulatory link between inflammation and angiogenesis［J］. Trends Immunol, 2004, 25(4): 201209. ［3］ Costantini S, Raucci R, De Vero T, et al. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach［J］. Cytokine, 2013, 10(64): 316321. ［4］ Belmadani A, Tran PB, Ren D, et al. The chemokine stromal cellderived factor1 regulates the migration of sensory neuron progenitors［J］. J Neurosci, 2005, 25(16): 39954003. ［5］ Helbig G, Christopherson KW 2nd, BhatNakshatri P, et al. NFkappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4［J］. J Biol Chem, 2003, 278(24): 2163121638. ［6］ Tomescu O, Xia SJ, Strezlecki D, et al. Inducible shortterm and stable longterm cell culture systems reveal that the PAX3FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression［J］. Lab Invest, 2004, 84(8): 10601070. ［7］ Castellone MD, Guarino V, De Falco V, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas［J］. Oncogene, 2004, 23(35): 59585967. ［8］ Jourdan P, Abbal C, Noraz N, et al. IL4 induces functiongal cellsurface expression of CXCR4 on human T cells［J］. J Immunol, 1998, 160(9): 41534157. ［9］ Jinquan T, Quan S, Jacobi HH, et al. CXC chemokine receptor4 expression and stromal celldrived factor 1αinduced chemotaxis in CD4+ T lymphocytes are regulated by interleukin4 and interleukin10［J］. Immunology, 2000, 99(3): 402410. ［10］ Gupta SK, Lysko PG, Pillarisetti K, et al. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines［J］. J Biol Chem, 1998, 273(7): 42824287. ［11］ MolinaOrtiz I, Bartolomé RA, HernándezVaras P, et al. Overexpression of Ecadherin on melanoma cells inhibits chemokinepromoted invasion involving p190RhoGAP/p120ctndependent inactivation of RhoA［J］. J Biol Chem, 2009, 284(22): 1514715157. ［12］ O′Boyle G, Swidenbnk I, Marshall H, et al. Inhibition of CXCR4CXCL12 chemotaxis in melanoma by AMD11070［J］. Br J Cancer, 2013, 108(8): 16341640. ［13］ Monteagudo C, Ramos D, PellínCarcelén A, et al. CCL27CCR10 and CXCL12CXCR4 chemokine ligandreceptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma［J］. Clin Exp Metastasis, 2012, 29(6): 625637. ［14］ Wang Q, Diao X, Sun J, et al. Regulation of VEGF, MMP9 and metastasis by CXCR4 in a prostate cancer cell line［J］. Cell Biol Int, 2011, 35(9): 897904. ［15］ KühneltLeddihn L, Müller H, Eisendle K, et al. Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: a potential prognostic value for CCR7 and CCR10?［J］. Arch Dermatol Res, 2012, 304(3): 185193. ［16］ Todaro M, D′Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes［J］. J Immunol, 2009, 182(11): 72877296. ［17］ Kim H. Will the stromaderived factor1alpha (CXCL12)/CXCR4 pathway become a major concern for advanced colorectal cancer?［J］. J Korean Soc Coloproctol, 2012, 28(1): 34. ［18］ Abedini F, Hosseinkhani H, Ismail M, et al. Cationized dextran nanoparticleencapsulated CXCR4siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer［J］. Int J Nanomedicine, 2012, 7: 41594168. ［19］ Hu T, Yao Y, Yu S, et al. Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer［J］. J Biomed Res, 2013, 27(4): 283290. ［20］ Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment［J］. Blood, 2006, 107(5): 17611767. ［21］ Boudot A, Kerdivel G, Habauzit D, et al. Differential estrogenregulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells［J］. PLoS One, 2011, 6(6): e20898. ［22］ Kochetkova M, Kumar S, McColl SR. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells［J］. Cell Death Differ, 2009, 16(5): 664673. ［23］ Righi E, Kashiwagi S, Yuan J, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer［J］. Cancer Res, 2011, 71(16): 55225534. ［24］ Hall JM, Korach KS. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ERCXCL12CXCR4 signaling axis［J］. Mol Carcinog, 2013, 52(9): 715725. ［25］ Wang J, Cai J, Han F, et al. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway［J］. Int J Gynecol Cancer, 2011, 21(6): 981987. ［26］ Li X, Ma Q, Xu Q, et al. SDF1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelialmesenchymal transition in vitro through noncanonical activation of Hedgehog pathway［J］. Cancer Lett, 2012, 322(2): 169176. ［27］ Dai X, Mao Z, Huang J, et al. The CXCL12/CXCR4 autocrine loop increases the metastatic potential of nonsmall cell lung cancer in vitro［J］. Oncol Lett, 2013, 5(1): 277282. ［28］ Wanger PL, Moo TA, Arora N, et al. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma［J］. Ann Surg Oncol, 2008, 15(10): 28332841. ［29］ Yuan L, Zhang H, Liu J, et al. Growth factor receptorSrcmediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration［J］. Mol Cancer, 2013, 12: 18.

[1]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[2]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[6]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[7]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[8]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[9]	张丽, 向卓, 王强, 毕经旺. CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381.
[10]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[11]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[12]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[13]	李佳璇, 封颖璐. 糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.
[14]	李雄安, 颜艳艳. 丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[15]	马培晗, 张灵敏, 路宁, 张明鑫. 麻醉对肝细胞癌复发转移的影响[J]. 国际肿瘤学杂志, 2023, 50(2): 117-121.

趋化因子受体4与肿瘤(此篇文章已撤销)

Chemokine receptor 4 and tumors

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价